Histone Deacetylase Inhibitor Upregulates Peroxisomal Fatty Acid Oxidation and Inhibits Apoptotic Cell Death in Abcd1-Deficient Glial Cells

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Singh, Jaspreet ^a   Khan, Mushfiquddin ^a   Pujol, Aurora ^b,c,d   Baarine, Mauhamad ^a   Singh, Inderjit ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER D1; BIM PROTEIN; CASPASE 3; CASPASE 9; ELONGASE OF VERY LONG CHAIN FATTY ACID; HISTONE DEACETYLASE INHIBITOR; LENTIVIRUS VECTOR; MEMBRANE ENZYME; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID; VORINOSTAT;

ABCD1 GENE; ADRENOLEUKODYSTROPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; CELL LOSS; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME SYNTHESIS; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE; GENE DELETION; GENE LOSS; GENE SILENCING; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; OLIGODENDROGLIA; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; FATTY ACIDS; HISTONE DEACETYLASE INHIBITORS; HUMANS; OXIDATION-REDUCTION; PEROXISOMES; RATS;

EID: 84880795860     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070712     Document Type: Article

References (90)

1. Moser HW, (1993) Lorenzo oil therapy for adrenoleukodystrophy: a prematurely amplified hope. Annals of neurology 34: 121-122.
2. Contreras M, Mosser J, Mandel JL, Aubourg P, Singh I, (1994) The protein coded by the X-adrenoleukodystrophy gene is a peroxisomal integral membrane protein. FEBS letters 344: 211-215.
3. Contreras M, Sengupta TK, Sheikh F, Aubourg P, Singh I, (1996) Topology of ATP-binding domain of adrenoleukodystrophy gene product in peroxisomes. Archives of biochemistry and biophysics 334: 369-379.
4. Singh I, Moser AE, Goldfischer S, Moser HW, (1984) Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proceedings of the National Academy of Sciences of the United States of America 81: 4203-4207.
5. Moser HW SK, Watkins PA, Powers J, Moser AB (2001) X-linked adrenoleukodystrophy. In: CR Scriver AB, Sly WS, Valle D, The Metabolic and Molecular Bases of Inherited Disease. NewYork: McGraw Hill. 3257-3301.
6. Khan M, Singh J, Gilg AG, Uto T, Singh I, (2010) Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy. Journal of lipid research 51: 1685-1695.
7. Singh J, Khan M, Singh I, (2009) Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. Journal of lipid research 50: 135-147.
8. Di Benedetto R, Denti MA, Salvati S, Attorri L, Di Biase A, (2009) PMP70 knock-down generates oxidative stress and pro-inflammatory cytokine production in C6 glial cells. Neurochemistry international 54: 37-42.
9. Khan M, Singh J, Singh I, (2008) Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. Journal of neurochemistry 106: 1766-1779.
10. Paintlia AS, Gilg AG, Khan M, Singh AK, Barbosa E, et al. (2003) Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiology of disease 14: 425-439.
11. Fourcade S, Lopez-Erauskin J, Galino J, Duval C, Naudi A, et al. (2008) Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Human molecular genetics 17: 1762-1773.
12. Powers JM, Liu Y, Moser AB, Moser HW, (1992) The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. Journal of neuropathology and experimental neurology 51: 630-643.
13. Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, et al. (2002) Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Human molecular genetics 11: 499-505.
14. Schluter A, Espinosa L, Fourcade S, Galino J, Lopez E, et al. (2012) Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. Human molecular genetics 21: 1062-1077.
15. Gilg AG, Singh AK, Singh I, (2000) Inducible nitric oxide synthase in the central nervous system of patients with X-adrenoleukodystrophy. Journal of neuropathology and experimental neurology 59: 1063-1069.
16. Takuma K, Baba A, Matsuda T, (2004) Astrocyte apoptosis: implications for neuroprotection. Progress in neurobiology 72: 111-127.
17. Jang J, Kang HC, Kim HS, Kim JY, Huh YJ, et al. (2011) Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Annals of neurology 70: 402-409.
18. Ofman R, Dijkstra IM, van Roermund CW, Burger N, Turkenburg M, et al. (2010) The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO molecular medicine 2: 90-97.
19. Khan M, Pahan K, Singh AK, Singh I, (1998) Cytokine-induced accumulation of very long-chain fatty acids in rat C6 glial cells: implication for X-adrenoleukodystrophy. Journal of neurochemistry 71: 78-87.
20. Fourcade S, Ruiz M, Guilera C, Hahnen E, Brichta L, et al. (2010) Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Human molecular genetics 19: 2005-2014.
21. Gondcaille C, Depreter M, Fourcade S, Lecca MR, Leclercq S, et al. (2005) Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. The Journal of cell biology 169: 93-104.
22. Singh I, Khan M, Key L, Pai S, (1998) Lovastatin for X-linked adrenoleukodystrophy. The New England journal of medicine 339: 702-703.
23. Berger J, Albet S, Bentejac M, Netik A, Holzinger A, et al. (1999) The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. European journal of biochemistry/FEBS 265: 719-727.
24. McGuinness MC, Zhang HP, Smith KD, (2001) Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy. Molecular genetics and metabolism 74: 256-263.
25. Singh I, Pahan K, Khan M, (1998) Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. FEBS letters 426: 342-346.
26. Uto T, Contreras MA, Gilg AG, Singh I, (2008) Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Developmental neuroscience 30: 410-418.
27. Pai GS, Khan M, Barbosa E, Key LL, Craver JR, et al. (2000) Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Molecular genetics and metabolism 69: 312-322.
28. Hoshi M, Kishimoto Y, (1973) Synthesis of cerebronic acid from lignoceric acid by rat brain preparation. Some properties and distribution of the-hydroxylation system. The Journal of biological chemistry 248: 4123-4130.
29. Singh I, Paintlia AS, Khan M, Stanislaus R, Paintlia MK, et al. (2004) Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain research 1022: 1-11.
30. Wilson R, Sargent JR, (1993) Lipid and fatty acid composition of brain tissue from adrenoleukodystrophy patients. Journal of neurochemistry 61: 290-297.
31. Stoppini L, Buchs PA, Muller D, (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173-182.
32. Eyüpoglu IY, Hahnen E, Buslei R, Siebzehnrübl FA, Savaskan NE, et al. (2005) Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93: 992-999.
33. Aubourg P, Dubois-Dalcq M, (2000) X-linked adrenoleukodystrophy enigma: how does the ALD peroxisomal transporter mutation affect CNS glia? Glia 29: 186-190.
34. Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, et al. (2004) Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Human molecular genetics 13: 2997-3006.
35. Singh J, Khan M, Singh I, (2011) HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes. Journal of lipid research 52: 2056-2069.
36. Holzinger A, Kammerer S, Berger J, Roscher AA, (1997) cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter. Biochemical and biophysical research communications 239: 261-264.
37. Kamijo K, Kamijo T, Ueno I, Osumi T, Hashimoto T, (1992) Nucleotide sequence of the human 70 kDa peroxisomal membrane protein: a member of ATP-binding cassette transporters. Biochimica et biophysica acta 1129: 323-327.
38. Kemp S, Wei HM, Lu JF, Braiterman LT, McGuinness MC, et al. (1998) Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nature medicine 4: 1261-1268.
39. Ferrer I, Kapfhammer JP, Hindelang C, Kemp S, Troffer-Charlier N, et al. (2005) Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Human molecular genetics 14: 3565-3577.
40. Fourcade S, Ruiz M, Camps C, Schluter A, Houten SM, et al. (2009) A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. American journal of physiology Endocrinology and metabolism 296: E211-221.
41. Albet S, Bentejac M, Savary S, Gondcaille C, Netik A, et al. (2001) Rat adrenoleukodystrophy-related (ALDR) gene: full-length cDNA sequence and new insight in expression. Biochimica et biophysica acta 1517: 257-269.
42. Flavigny E, Sanhaj A, Aubourg P, Cartier N, (1999) Retroviral-mediated adrenoleukodystrophy-related gene transfer corrects very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts: implications for therapy. FEBS letters 448: 261-264.
43. Netik A, Forss-Petter S, Holzinger A, Molzer B, Unterrainer G, et al. (1999) Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Human molecular genetics 8: 907-913.
44. Asheuer M, Bieche I, Laurendeau I, Moser A, Hainque B, et al. (2005) Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Human molecular genetics 14: 1293-1303.
45. Forss-Petter S, Werner H, Berger J, Lassmann H, Molzer B, et al. (1997) Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. Journal of neuroscience research 50: 829-843.
46. Kobayashi T, Shinnoh N, Kondo A, Yamada T, (1997) Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochemical and biophysical research communications 232: 631-636.
47. Lu JF, Lawler AM, Watkins PA, Powers JM, Moser AB, et al. (1997) A mouse model for X-linked adrenoleukodystrophy. Proceedings of the National Academy of Sciences of the United States of America 94: 9366-9371.
48. Sharp P, Johnson D, Poulos A, (1991) Molecular species of phosphatidylcholine containing very long chain fatty acids in human brain: enrichment in X-linked adrenoleukodystrophy brain and diseases of peroxisome biogenesis brain. Journal of neurochemistry 56: 30-37.
49. Valianpour F, Selhorst JJ, van Lint LE, van Gennip AH, Wanders RJ, et al. (2003) Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry. Molecular genetics and metabolism 79: 189-196.
50. Tvrdik P, Asadi A, Kozak LP, Nedergaard J, Cannon B, et al. (1997) Cig30, a mouse member of a novel membrane protein gene family, is involved in the recruitment of brown adipose tissue. The Journal of biological chemistry 272: 31738-31746.
51. Tvrdik P, Westerberg R, Silve S, Asadi A, Jakobsson A, et al. (2000) Role of a new mammalian gene family in the biosynthesis of very long chain fatty acids and sphingolipids. The Journal of cell biology 149: 707-718.
52. Brolinson A, Fourcade S, Jakobsson A, Pujol A, Jacobsson A, (2008) Steroid hormones control circadian Elovl3 expression in mouse liver. Endocrinology 149: 3158-3166.
53. Bottelbergs A, Verheijden S, Hulshagen L, Gutmann DH, Goebbels S, et al. (2010) Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes. Glia 58: 1532-1543.
54. Kassmann CM, Lappe-Siefke C, Baes M, Brugger B, Mildner A, et al. (2007) Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nature genetics 39: 969-976.
55. Singh I, Pujol A, (2010) Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. Brain pathology 20: 838-844.
56. Hein S, Schonfeld P, Kahlert S, Reiser G, (2008) Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Human molecular genetics 17: 1750-1761.
57. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G, (1998) Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proceedings of the National Academy of Sciences of the United States of America 95: 4386-4391.
58. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
59. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, et al. (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809.
60. Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, et al. (1996) Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. The Journal of experimental medicine 183: 1957-1964.
61. Song Q, Lees-Miller SP, Kumar S, Zhang Z, Chan DW, et al. (1996) DNA-dependent protein kinase catalytic subunit: a target for an ICE-like protease in apoptosis. The EMBO journal 15: 3238-3246.
62. Eyupoglu IY, Hahnen E, Buslei R, Siebzehnrubl FA, Savaskan NE, et al. (2005) Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. Journal of neurochemistry 93: 992-999.
63. Moser HW, Powers JM, Smith KD, (1995) Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil. Brain pathology 5: 259-266.
64. Singh I, Moser HW, Moser AB, Kishimoto Y, (1981) Adrenoleukodystrophy: impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex. Biochemical and biophysical research communications 102: 1223-1229.
65. van Roermund CW, Visser WF, Ijlst L, Waterham HR, Wanders RJ, (2011) Differential substrate specificities of human ABCD1 and ABCD2 in peroxisomal fatty acid beta-oxidation. Biochimica et biophysica acta 1811: 148-152.
66. Singh I, Moser AE, Moser HW, Kishimoto Y, (1984) Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatric research 18: 286-290.
67. Kemp S, Valianpour F, Denis S, Ofman R, Sanders RJ, et al. (2005) Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Molecular genetics and metabolism 84: 144-151.
68. Ren D, Tu HC, Kim H, Wang GX, Bean GR, et al. (2010) BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 330: 1390-1393.
69. McGuinness MC, Griffin DE, Raymond GV, Washington CA, Moser HW, et al. (1995) Tumor necrosis factor-alpha and X-linked adrenoleukodystrophy. Journal of neuroimmunology 61: 161-169.
70. Kurokawa M, Kornbluth S, (2009) Caspases and kinases in a death grip. Cell 138: 838-854.
71. Acarin L, Villapol S, Faiz M, Rohn TT, Castellano B, et al. (2007) Caspase-3 activation in astrocytes following postnatal excitotoxic damage correlates with cytoskeletal remodeling but not with cell death or proliferation. Glia 55: 954-965.
72. Asano J, Suzuki Y, Yajima S, Inoue K, Shimozawa N, et al. (1994) Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain & development 16: 454-458.
73. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, et al. (1993) A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. The New England journal of medicine 329: 745-752.
74. Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, et al. (2000) Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 356: 713-718.
75. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
76. Genin EC, Geillon F, Gondcaille C, Athias A, Gambert P, et al. (2011) Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2). The Journal of biological chemistry 286: 8075-8084.
77. Silva-Zolezzi I, Hebron K, Mihalik S, Thomas G, Valle D, Jimenez-Sanchez G (2003) Abcd3-/- mice have a non-shivering thermogenesis defect related to a disturbance in fasting fuel homeostasis; Los Angeles, California. The American Society of Human Genetics. 199.
78. Galea E, Launay N, Portero-Otin M, Ruiz M, Pamplona R,et al. (2012) Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: A paradigm for multifactorial neurodegenerative diseases? Biochimica et biophysica acta.
79. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America 100: 2041-2046.
80. Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, et al. (2011) Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proceedings of the National Academy of Sciences of the United States of America 108: 5620-5625.
81. Lu J, Yang C, Chen M, Ye DY, Lonser RR, et al. (2011) Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America 108: 21200-21205.
82. Chen SH, Wu HM, Ossola B, Schendzielorz N, Wilson BC, et al. (2012) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. British journal of pharmacology 165: 494-505.
83. Cenik B, Sephton CF, Dewey CM, Xian X, Wei S, et al. (2011) Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. The Journal of biological chemistry 286: 16101-16108.
84. Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, et al. (2010) SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Human molecular genetics 19: 1492-1506.
85. Hashioka S, Klegeris A, McGeer PL, (2012) The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-gamma. Journal of neuroinflammation 9: 113.
86. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proceedings of the National Academy of Sciences of the United States of America 99: 2995-3000.
87. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, et al. (2007) Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 122: 596-606.
88. Li Y, Liu B, Zhao H, Sailhamer EA, Fukudome EY, et al. (2009) Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents. Shock 32: 517-523.
89. Bai G, Wei D, Zou S, Ren K, Dubner R, (2010) Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Molecular pain 6: 51.
90. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, et al. (2010) Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28: 3623-3629.